More on that story in a moment. But we begin tonight with a decline in the biotech sector. The decline in that sector, its worst of the year, was fueled not by a failed drug trial but by president ial hopeful Hillary Clinton. The nasdaq biotech index fell about 4 1 2 after clinton said in a tweet that as president shed crack down on what she sees as price gouging in the pharmaceutical industry. She promised more details tomorrow. Now, those comments were in response to a report in the New York Times of a 5,000 price increase, virtually overnight, in a 62yearold specialty drug. Now, weve talked a lot about the high cost of breakthrough new drugs coming to market. But as meg tirrell reports, older drugs arent immune. Reporter for a Small Company its making big waves for the drug industry. Turing pharmaceuticals, a private Company Founded by a former hedge fund manager, is the target of outrage over the price of its drug deraprin. The medicine cost 13. 50 a tablet before turing acquired t
More on that story in a moment. But we begin tonight with a decline in the biotech sector. The decline in that sector, its worst of the year, was fueled not by a failed drug trial but by president ial hopeful Hillary Clinton. The nasdaq biotech index fell about 4 1 2 after clinton said in a tweet that as president shed crack down on what she sees as price gouging in the pharmaceutical industry. She promised more details tomorrow. Now, those comments were in response to a report in the New York Times of a 5,000 price increase, virtually overnight, in a 62yearold specialty drug. Now, weve talked a lot about the high cost of breakthrough new drugs coming to market. But as meg tirrell reports, older drugs arent immune. Reporter for a Small Company its making big waves for the drug industry. Turing pharmaceuticals, a private Company Founded by a former hedge fund manager, is the target of outrage over the price of its drug deraprin. The medicine cost 13. 50 a tablet before turing acquired t
More on that story in a moment. But we begin tonight with a decline in the biotech sector. The decline in that sector, its worst of the year, was fueled not by a failed drug trial but by president ial hopeful Hillary Clinton. The nasdaq biotech index fell about 4 1 2 after clinton said in a tweet that as president shed crack down on what she sees as price gouging in the pharmaceutical industry. She promised more details tomorrow. Now, those comments were in response to a report in the New York Times of a 5,000 price increase, virtually overnight, in a 62yearold specialty drug. Now, weve talked a lot about the high cost of breakthrough new drugs coming to market. But as meg tirrell reports, older drugs arent immune. Reporter for a Small Company its making big waves for the drug industry. Turing pharmaceuticals, a private Company Founded by a former hedge fund manager, is the target of outrage over the price of its drug deraprin. The medicine cost 13. 50 a tablet before turing acquired t